Eli Lilly’s decision to give two distinctive brand names to tirzepatide, which is approved for type 2 diabetes and now chronic weight management, indicates how differently the company plans to market the two indications.
Last week, it announced that its version of the weight management drug is called Zepbound, while the same drug is branded Mounjaro for type 2 diabetes.
“Diabetic patients and obese patients have different needs,” a Lilly spokesperson said in an email. “The different brands allow Lilly to educate and provide resources and tools so healthcare professionals and patients can successfully get started on Zepbound.”
Unlock this article instantly by becoming a free subscriber.
You’ll have access to free articles every month and you can personalize the newsletters sent to your inbox each week, including the latest news.
Gn En gealth